Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

por Detke, Holland C, Zhao, Fangyi, Witte, Michael M
Publicado 2012

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study

por McDonnell, David P., Landry, John, Detke, Holland C.
Publicado 2014

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective

por Heres, Stephan, Kraemer, Susanne, Bergstrom, Richard F., Detke, Holland C.
Publicado 2014

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment

por Detke, Holland C., Lauriello, John, Landry, John, McDonnell, David P.
Publicado 2014

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being

por Anand, Ernie, Berggren, Lovisa, Landry, John, Tóth, Ágoston, Detke, Holland C
Publicado 2016

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

por Atkins, Susan, Detke, Holland C, McDonnell, David P, Case, Michael G, Wang, Shufang
Publicado 2014

Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination

por Walker, Daniel J., DelBello, Melissa P., Landry, John, D’Souza, Deborah N., Detke, Holland C.
Publicado 2017

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice

por Bushe, Chris J, Falk, Deborah, Anand, Ernie, Casillas, Marta, Perrin, Elena, Chhabra-Khanna, Rashna, Detke, Holland C
Publicado 2015

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

por Detke, Holland C., Goadsby, Peter J., Wang, Shufang, Friedman, Deborah I., Selzler, Katherine J., Aurora, Sheena K.
Publicado 2018

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies

por Detke, Holland C., Millen, Brian A., Zhang, Qi, Samaan, Karen, Ailani, Jessica, Dodick, David W., Aurora, Sheena K.
Publicado 2019

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

por Detke, Holland C, McDonnell, David P, Brunner, Elizabeth, Zhao, Fangyi, Sorsaburu, Sebastian, Stefaniak, Victoria J, Corya, Sara A
Publicado 2010

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective...

por Jones, Meghan E., Andrews, Jeffrey S., Faries, Douglas E., Landry, John, Xu, Jenny, Detke, Holland C., Chhabra-Khanna, Rashna, McDonnell, David P.
Publicado 2015

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

por Reuter, Uwe, Lucas, Christian, Dolezil, David, Hand, Austin L., Port, Martha D., Nichols, Russell M., Stroud, Chad, Tockhorn-Heidenreich, Antje, Detke, Holland C.
Publicado 2021

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

por McDonnell, David P, Detke, Holland C, Bergstrom, Richard F, Kothare, Prajakti, Johnson, Jason, Stickelmeyer, Mary, Sanchez-Felix, Manuel V, Sorsaburu, Sebastian, Mitchell, Malcolm I
Publicado 2010

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

por Ascher-Svanum, Haya, Zhao, Fangyi, Detke, Holland C, Nyhuis, Allen W, Lawson, Anthony H, Stauffer, Virginia L, Montgomery, William, Witte, Michael M, McDonnell, David P
Publicado 2011